PACT – Clinician
New Clinical Trial and Research

Trial title	A Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to determine the safety, tolerability, immunogenicity and pharmacokinetic properties of LASN01 in healthy subjects and in patients with idiopathic pulmonary fibrosis or thyroid eye disease
Trial synopsis	This is four part Phase 1 study evaluating the safety, tolerability, immunogenicity, and PK of single and multiple IV doses of LASN01 in healthy subjects and in patients with ILD/IPF and TED. Parts A & B will comprise of a single and multiple-dose, sequential-group design in healthy subjects. Recruitment for these parts is completed. Part D will comprise of a multiple-dose, sequential- group design in patients with TED. We are looking for participants for Part C of the study only: Part C will comprise of a multiple-dose design in patients with IPF or PF- ILD.
Investigational medicinal product, comparator and randomisation	LASN01 or placebo (approximately 3:1 randomization to active treatment versus placebo).
Disease target	IPF, PF-ILD
Sponsor	Lassen Therapeutics 1
Duration	18 weeks
Trial Status	Recruiting
Trial phase	Phase 1
Key inclusion criteria	As above
Key exclusion criteria	As above
Primary endpoint	As above
Number of participants sought	8 to 12 participants for Part C
Lead site(s) in Australia	Nucleus Network Melbourne
Lead site(s) in New Zealand	NA
Additional sites	Nucleus Network Brisbane
Contact	pactcoordinator@cre-pf.org.au